Literature DB >> 30109356

Quetiapine ameliorates collagen-induced arthritis in mice via the suppression of the AKT and ERK signaling pathways.

Yi-Ju Pan1,2, Wei-Hsun Wang3,4, Tzu-Yao Huang5, Wei-Hsiang Weng5, Chun-Kai Fang6, Yu-Chan Chen7, Jeng-Jong Hwang8,9.   

Abstract

OBJECTIVE AND
DESIGN: To investigate the amelioration effects of quetiapine on rheumatoid arthritis with RAW 264.7 macrophage and collagen-induced arthritis (CIA) DBA/1J mouse model.
SUBJECTS: RAW 264.7 macrophage and DBA/1J mice. TREATMENT: Lipopolysaccharide and collagen.
METHODS: RAW 264.7 macrophages stimulated by lipopolysaccharide (LPS) followed by quetiapine treatments were investigated. Activations of CD80 and CD86 were analyzed by flow cytometry. Pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β were analyzed by ELISA. Proteins involved in signaling pathways related to the formation of rheumatoid arthritis were assayed by Western blotting. Therapeutic efficacy of quetiapine in CIA mouse model was also assayed. 18F-FDG/micro-PET was used to monitor the inflammation status in the joints, and the severity of bone erosion was evaluated with micro-CT and H&E staining.
RESULTS: The inhibition of pro-inflammatory cytokines by quetiapine was found through the ERK and AKT phosphorylation and subsequent NF-κB and CREB signaling pathways. Pro-inflammatory cytokines such as IL-17, IL-6 and IL-1β were decreased, while immunosuppressive factors such as TGF-β and IL-10 were increased in CIA mice treated with quetiapine. Notably, no uptake of 18F-FDG and bone erosion was found with micro-PET images on days 32 and 43 in the quetiapine-treated and normal control groups. However, significant uptake of 18F-FDG could be observed in the CIA group during the same time course. Similar results were further verified with ex vivo autoradiography.
CONCLUSION: Taken together, these results suggest that quetiapine is a potential anti-inflammatory drug, and may be used as an adjuvant for the treatment of rheumatoid arthritis.

Entities:  

Keywords:  AKT; Collagen-induced arthritis; ERK; Quetiapine

Mesh:

Substances:

Year:  2018        PMID: 30109356     DOI: 10.1007/s00011-018-1176-1

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  46 in total

Review 1.  The burden of depression in patients with rheumatoid arthritis.

Authors:  C Dickens; F Creed
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

Review 2.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

3.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

4.  Interleukin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis.

Authors:  T Kasama; R M Strieter; N W Lukacs; P M Lincoln; M D Burdick; S L Kunkel
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

5.  Assessment of disease activity in rheumatoid arthritis with (18)F-FDG PET.

Authors:  Catherine Beckers; Clio Ribbens; Béatrice André; Stefaan Marcelis; Olivier Kaye; Luc Mathy; Marie-Joëlle Kaiser; Roland Hustinx; Jacqueline Foidart; Michel G Malaise
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

Review 6.  Dendritic cells as targets for therapy in rheumatoid arthritis.

Authors:  Shaukat Khan; Jeffrey D Greenberg; Nina Bhardwaj
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

7.  IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis.

Authors:  Young-Mee Moon; Bo-Young Yoon; Yang-Mi Her; Hye-Joa Oh; Jae-Seon Lee; Kyoung-Woon Kim; Seon-Yeong Lee; Yun-Ju Woo; Kyung-Su Park; Sung-Hwan Park; Ho-Youn Kim; Mi-La Cho
Journal:  Arthritis Res Ther       Date:  2012-11-13       Impact factor: 5.156

Review 8.  Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis.

Authors:  Tobias Braun; Jochen Zwerina
Journal:  Arthritis Res Ther       Date:  2011-07-28       Impact factor: 5.156

Review 9.  Mast cells in inflammatory arthritis.

Authors:  Peter A Nigrovic; David M Lee
Journal:  Arthritis Res Ther       Date:  2004-11-02       Impact factor: 5.156

Review 10.  Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma.

Authors:  Wendy Anne Boivin; Dawn Michelle Cooper; Paul Ryan Hiebert; David James Granville
Journal:  Lab Invest       Date:  2009-09-21       Impact factor: 5.502

View more
  3 in total

1.  Prediction of Targets of Curculigoside A in Osteoporosis and Rheumatoid Arthritis Using Network Pharmacology and Experimental Verification.

Authors:  Jiawen Han; Minjie Wan; Zhanchuan Ma; Cong Hu; Huanfa Yi
Journal:  Drug Des Devel Ther       Date:  2020-11-26       Impact factor: 4.162

Review 2.  The Akt pathway in oncology therapy and beyond (Review).

Authors:  George Mihai Nitulescu; Maryna Van De Venter; Georgiana Nitulescu; Anca Ungurianu; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Daniela Grădinaru; Aristides Tsatsakis; Dimitris Tsoukalas; Demetrios A Spandidos; Denisa Margina
Journal:  Int J Oncol       Date:  2018-10-16       Impact factor: 5.650

3.  Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis.

Authors:  Kai Guo; Xin Bu; Chongfei Yang; Xiaorui Cao; Huan Bian; Qingsheng Zhu; Jinyu Zhu; Dawei Zhang
Journal:  Front Immunol       Date:  2019-01-10       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.